Navigation Links
NxStage Applauds Array of Studies To Be Presented at American Society of Nephrology Meeting
Date:11/5/2008

Daily Home Hemodialysis and Renal Replacement Therapy in Critical Care Receive Significant Attention

LAWRENCE, Mass., Nov. 5 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that the annual scientific meeting of the American Society of Nephrology (ASN) will feature multiple podium and poster presentations that explore the benefits and uses of daily home hemodialysis (DHD) and critical care renal replacement therapy.

These independent studies are in addition to the presentation of interim results from the FREEDOM Study, "Daily Home HD Improves Quality of Life (QoL) Measures, Depressive Symptoms and Recovery Time: Interim Results from the FREEDOM Study," which takes place on Friday, November 7 at 4pm, F-FC230. On behalf of the FREEDOM study, co-investigator Frederic Finkelstein of Yale University will report and explain 4-month results which show that daily home hemodialysis with the NxStage System One significantly reduces recovery time, reduces depressive symptoms, and improves physical and mental quality-of-life. The ongoing FREEDOM Study is sponsored by NxStage, and additional information may be gathered at http://www.clinicaltrials.gov.

Two ASN curriculum sessions will feature discussion of home and/or more frequent hemodialysis therapies. These include "Epidemiology, Outcomes, and Clinical Trials in Dialysis" (Friday, November 7 at 4:00-6:00 PM in Room 204) and "Outcomes Associated with Dialysis Modality and Delivery" (Friday, November 7 at 4:00-6:00 PM in Room 204 B/C).

Selected independent studies slated for presentation at ASN include:

HOME/DAILY HEMODIALYSIS

-- "Comparison of blood pressure volatility between conventional and

short daily hemodialysis." Miho Murashima presents on behalf of his

colleagues from the Hospital of the University of Pennsylvania that not

only does daily dialysis reduce blood pressure and the requirement for

antihypertensive medications versus conventional thrice-weekly dialysis,

but it also reduces the relative risk of intradialytic hypotensive

episodes by 86% (TH-PO604, 11/6, 10:00 AM).

-- "Differences in Hemodynamic Parameters and CV Markers between

Patients Undergoing Thrice Weekly or More Frequent HD." Bhupinder

Virk of Satellite Healthcare concludes that home daily hemodialysis

patients appear to have less volume overload and less evidence for

myocardial injury based upon significant reductions in cardiovascular

(CV) markers Troponin T (cTnT) and proBNP in the home daily dialysis

group vs. a matched conventional in-center dialysis cohort (F-PO1706,

11/7, 10:00 AM).

-- "Calcium mass balance during short daily home hemodialysis with a

3.0 mEq/L calcium dialysate." Brent Miller of Washington

University in St. Louis presents that hemodialysis using an average of

approximately 24 L/session of dialysate with a calcium concentration of

3.0 mEq/L with the NxStage System One yields a net calcium balance of

-54 mg per treatment at usual prescribed parameters (SA-PO2691, 11/8,

10:00 AM).

-- "Recovery of renal function noted in a short daily low volume home

dialysis program." Michael Kraus of Indiana University reports that

6 of 111 daily hemodialysis patients have regained kidney function, a

rate higher than that reported by the USRDS (PUB387).

-- "Quality of life perception by in-center vs. home dialysis

patients." Eduardo Lacson presents data on health related

quality-of-life (HR-QOL) including over 41,000 in-center HD patients and

approximately 2,300 home HD and PD patients gathered in 2006 in

Fresenius Medical Care North America facilities, and concludes that both

physical and mental HR-QOL scores are significantly higher in home

patients, even after adjustment for multiple factors (TH-PO797, 11/6,

10:00 AM).

-- "Home Hemodialysis (HHD), Facility Hemodialysis (FHD) and

Peritoneal Dialysis (PD) and mortality in Australian and New Zealand

patient populations" and "Home hemodialysis (HHD) is

associated with lower mortality than facility hemodialysis (FHD) in

Australian and New Zealand populations." Mike Marshall and

colleagues from Queen Elizabeth hospital in Australia discuss findings

that HHD mortality is significantly lower, even after adjustments, than

that of FHD and PD, and the benefit is most significant in patients with

fewer comorbidities (F-FC231, 11/7, 4:12 PM and F-FC319, 11/7, 5:48 PM,

respectively).

CRITICAL CARE RENAL REPLACEMENT THERAPIES

-- "Putting the Continuous in CRRT." Michael Kraus of Indiana

University presents experience with higher-blood flow (approximately 300

mL/min) continuous renal replacement therapy (CRRT) in which 95% of the

CRRT prescription is actually delivered despite 70% of treatments being

delivered without anticoagulation. This compares favorably to reported

dose delivery in previous published studies in which lower blood flows

were used (SA-PO2578, 11/8, 10:00 AM)

-- "Pharmacokinetics, Dosing, and Monitoring Practices of Vancomycin

in Patients Undergoing CVVHD with High Blood and Dialysate Flow

Rates." Francis Wilson and Jeff Burns of the Hospital of the

University of Pennsylvania present vancomycin clearance patterns with

CRRT and suggest loading and subsequent dosing

recommendations.(SA-PO3071, 11/18, 10:00 AM)

-- "Management of Severe Hyperkalemia with Continuous Veno-venous

Hemodialysis." Anjali Ganda and colleagues at Columbia University

conclude that continuous veno-venous hemodialysis (CVVHD) using high

dialysate flows may represent a safe and acceptable alternative to

traditional HD in the acute management of severe hyperkalemia (PUB385).

"It is exciting to see the increasing volume of clinician-initiated research activity focused on daily home hemodialysis and critical care therapy," said Jeff Burbank, CEO of NxStage Medical, Inc. "For daily home hemodialysis, in particular, this research reflects the growing presence of DHD in mainstream patient care, and deepens our understanding of this modality in both clinical and economic terms."

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.

VP, Investor Relations

ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
2. NxStage Reports Third Quarter 2008 Financial Results
3. NxStage Appoints New Member to Its Board of Directors and Announces Resignation of Board Member
4. NxStage Announces Presentation of Data at the American Society of Nephrologys Renal Week 2008 Annual Meeting
5. NxStage Reports Second Quarter 2008 Financial Results
6. NxStage Announces $43 Million Private Placement of Equity Securities
7. NxStage Medical Reports First Quarter 2008 Results
8. NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets
9. Tsongas Visits Lawrence-based Medical Device Maker NxStage Medical, Inc.
10. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
11. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign ... for the Access to Contraception for Women Servicemembers and Dependents Act of 2017. ... (D-CA), will help to ensure that all members of the Armed Forces receive ...
(Date:4/28/2017)... ... , ... It's not always common knowledge whether or not a certain sickness ... to whether or not they are contagious, and most people don't know the answer ... took a look into the matter. , They discovered that the main reason ...
(Date:4/28/2017)... UT (PRWEB) , ... April 28, 2017 , ... Beginning ... some of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ... be changing the formula in the following ways:, , Removal ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it ... 19 hours without sleep can compromise motor reaction time, which can increase the risk of ... is sharing the following tips from the NSF to help you sleep better and feel ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: April ... “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on her ... Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she was ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... 2017 The Global Effective Microorganisms (EM) ... report has covered and analysed the potential of Global Effective ... size, shares and growth factors. The report identifies and analyses ... in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, spread ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology: